{"id":"hum0240","version":1,"url":"https://humandbs.dbcls.jp/research/hum0240/v1","datePublished":"2020-10-30","versions":[{"version":1,"datePublished":"2020-10-30"}],"title":{"ja":"中枢神経原発悪性リンパ腫の全ゲノムシーケンス解析","en":"Whole genome sequence analysis in patients with primary central nervous system lymphomas"},"summary":{"aims":{"ja":"中枢神経原発悪性リンパ腫の診断マーカーならびに治療標的の探索研究","en":"To explore molecular targets of primary central nervous system lymphoma (PCNSL)"},"methods":{"ja":"原発腫瘍組織と末梢血から抽出したgenomic DNAを用いたTarget Capture Sequencing解析","en":"Target amplicon sequencing analysis was performed using Target Capture technology (NGS) on Cancer Panel"},"targets":{"ja":"中枢神経原発悪性リンパ腫","en":"PCNSL patients"},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"中枢神経原発悪性リンパ腫：28症例\n（日本人）","en":"28 PCNSL patinets\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Target Capture）","en":"NGS\n(Target Capture)"}},"releaseNote":{"ja":"中枢神経原発悪性リンパ腫28症例の原発腫瘍組織および末梢血から抽出したDNAを用いたTarget Capture Sequencing解析結果をfastqファイルにて提供する。","en":"DNAs extracted from primary tumor tissues and peripheral blood cells of 28 patients with PCNSL were used for a target capture sequencing analysis. Fastq files are provided."},"dataProviders":[{"name":{"ja":"山中 龍也","en":"Ryuya Yamanaka"},"organization":{"name":{"ja":"京都府立医科大学 腫瘍分子標的治療学","en":"Laboratory of Molecular Targeted Therapy for Cancer, Kyoto Prefectural University of Medicine"}}}],"researchProjects":[{"name":{"ja":"Genome-wide analysis in patients with primary central nervous system lymphomas.","en":"Genome-wide analysis in patients with primary central nervous system lymphomas."},"url":{"ja":null,"en":null}}],"grants":[{"title":{"ja":"脳リンパ腫のゲノム解析成果を基盤とした分子標的創薬・バイオマーカー研究","en":"Exploring molecular targets for primary central nervous system lymphomas based on genome-wide analysis."},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["16H05441"]},{"title":{"ja":"脳悪性リンパ腫の全エクソンシーケンスを応用したゲノム創薬・バイオマーカー研究","en":"Development of molecular targeted therapy for primary central nervous system lymphomas."},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["24390347"]}],"relatedPublications":[{"title":"Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma","doi":"https://doi.org/10.18632/oncotarget.25463","datasets":["JGAD000361"]},{"title":"Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma","doi":"https://doi.org/10.1371/journal.pone.0251272","datasets":["JGAD000361"]}],"datasets":["JGAD000361"],"controlledAccessUsers":[]}